Paula Rauch

BioSpring is a leading industry expert in oligonucleotide science and technology, specializing in high-quality cGMP manufacturing and analytics for commercial programs and clinical phases I-III, in addition to preclinical material supply and diagnostic manufacturing. We are a privately owned company of ~600 employees committed to providing expert support through all phases and regulatory filings, including highly flexible and customizable solutions to accelerate therapeutic programs through the entire drug development lifecycle. Headquartered in the center of Europe, in Frankfurt, Germany, we are an international company with a subsidiary in the United States and a local presence in Japan. Our global clients can rely on our quality and expertise, guided by our passion for innovation and more than 27 years of experience. Our aim is a highly collaborative partnership to unleash the full potential of our clients’ technology – making great strides and breakthroughs possible. We are driven by our desire for a healthier world. Restoring hope in patients living with debilitating diseases is our daily motivation to progress novel nucleic acid-based therapies to their commercial promise. Privacy notice: https://www.biospring.de/datenschutz-socialmedia/